MoonLake Immunotherapeutics
MLTX
MLTX
113 hedge funds and large institutions have $2.99B invested in MoonLake Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
15% less capital invested
Capital invested by funds: $3.53B → $2.99B (-$544M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
Holders
113
Holding in Top 10
4
Calls
$22.9M
Puts
$26.9M
Top Buyers
| 1 | +$38.1M | |
| 2 | +$26.3M | |
| 3 | +$25.7M | |
| 4 |
Holocene Advisors
New York
|
+$24.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
Top Sellers
| 1 | -$62.8M | |
| 2 | -$26.8M | |
| 3 | -$14.4M | |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$14M |
| 5 |
SIG
Senator Investment Group
New York
|
-$9.36M |